Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Y Choi

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Blood|November 11, 2021
Improving the outlook for TP53-aberrant CLLMichael Y Choi
Oncology (Williston Park, N.Y.)|September 17, 2016
How Do Targeted Therapies Change the Management of Indolent Lymphomas?Michael Y Choi, Thomas J Kipps
Cancer Journal (Sudbury, Mass.)|November 26, 2019
Targeted Therapy in Chronic Lymphocytic LeukemiaThomas J Kipps, Michael Y Choi
Biochemical and Biophysical Research Communications|August 29, 2012
Non-canonical microRNAs miR-320 and miR-702 promote proliferation in Dgcr8-deficient embryonic stem cellsByeong-Moo Kim, Michael Y Choi
Gastroenterology|July 1, 2009
New insights into the role of Hedgehog signaling in gastrointestinal development and cancerByeong-Moo Kim, Michael Y Choi
Cancer Journal (Sudbury, Mass.)|September 26, 2012
Inhibitors of B-cell receptor signaling for patients with B-cell malignanciesMichael Y Choi, Thomas J Kipps
Biomolecular Concepts|November 6, 2014
Update on non-canonical microRNAsAhmed Maher Abdelfattah, Chanhyun Park, Michael Y Choi
Best Practice & Research. Clinical Haematology|October 16, 2016
The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptorMichael Y Choi, Manoj Kumar Kashyap, Deepak Kumar
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2019
SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic LeukemiaMichael Y Choi, Huan-You Wang, Thomas J Kipps
Cancers|December 23, 2022
Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter's SyndromeBenjamin M Heyman, Michael Y Choi, Thomas J Kipps
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Blood|November 11, 2021
Improving the outlook for TP53-aberrant CLLMichael Y Choi
Oncology (Williston Park, N.Y.)|September 17, 2016
How Do Targeted Therapies Change the Management of Indolent Lymphomas?Michael Y Choi, Thomas J Kipps
Cancer Journal (Sudbury, Mass.)|November 26, 2019
Targeted Therapy in Chronic Lymphocytic LeukemiaThomas J Kipps, Michael Y Choi
Biochemical and Biophysical Research Communications|August 29, 2012
Non-canonical microRNAs miR-320 and miR-702 promote proliferation in Dgcr8-deficient embryonic stem cellsByeong-Moo Kim, Michael Y Choi
Gastroenterology|July 1, 2009
New insights into the role of Hedgehog signaling in gastrointestinal development and cancerByeong-Moo Kim, Michael Y Choi
Cancer Journal (Sudbury, Mass.)|September 26, 2012
Inhibitors of B-cell receptor signaling for patients with B-cell malignanciesMichael Y Choi, Thomas J Kipps
Biomolecular Concepts|November 6, 2014
Update on non-canonical microRNAsAhmed Maher Abdelfattah, Chanhyun Park, Michael Y Choi
Best Practice & Research. Clinical Haematology|October 16, 2016
The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptorMichael Y Choi, Manoj Kumar Kashyap, Deepak Kumar
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2019
SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic LeukemiaMichael Y Choi, Huan-You Wang, Thomas J Kipps
Cancers|December 23, 2022
Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter's SyndromeBenjamin M Heyman, Michael Y Choi, Thomas J Kipps
Pageof 5